Figure 6:

Association between individual statins type used by diabetics both pre- and post-diagnosis of HCC and risk of death after diagnosis of HCC. ^a Adjusted for age (continuous), sex, and post-diagnosis statins type (pravastatin, rosuvastatin, atorvastatin, lovastatin, simvastatin, fluvastatin, and non-users). ^b Adjusted for everything in “^a” plus year of diagnosis, race, marital status, neighborhood income level, percent with 4-year college in neighborhood, tumor grade, tumor stage, chemotherapy, radiation, Charlson comorbidity index, diabetes severity index, obesity, presence of COPD, dyslipidemia, and hepatitis as categorized in Table 1. ^c Adjusted for age, sex, and pre-diagnosis statins type (pravastatin, rosuvastatin, atorvastatin, lovastatin, simvastatin, fluvastatin, and non-users). ^d Adjusted for everything in “^c” plus year of diagnosis, race, marital status, neighborhood income level, percent with 4-year college in neighborhood, tumor grade, tumor stage, chemotherapy, radiation, Charlson comorbidity index, obesity, COPD, dyslipidemia, diabetes, diabetic comorbidities index, and hepatitis status as categorized in Table 1. Abbreviation: HCC, hepatocellular carcinoma; NE, not estimated due to small numbers (less than 10 individuals in the group).